Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, PLW

Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics


OXFORD, England, July 15, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate held by Evox and further reinforces the Company's leading position within the field of exosome-mediated RNA drug delivery.

The recently issued US patent (U.S. Patent 10,704,047) provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.

Dr Per Lundin, Chief Operating Officer of Evox, commented: "We are very pleased to have been granted another foundational patent, reflecting our scientific and IP leadership in the exosome therapeutics space. This is another significant development that gives Evox dominant coverage in exosome-mediated RNA delivery, as well as key steps in the manufacturing process."

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, added: "Over the past decade, Evox has built an unrivalled global patent estate with broad and deep coverage of the key applications of exosome therapeutics. This recent grant represents a great addition of our IP position and further reinforces Evox's leading position as the partner of choice in the field of exosome therapeutics."

About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Our proprietary DeliverEXTM platform enables loading of exosomes with diverse drug cargos, leverages the unique tissue targeting properties of exosomes, and supports proprietary manufacturing and purification methods for advanced exosome therapeutics. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

For further information visit: www.evoxtherapeutics.com

 

SOURCE Evox Therapeutics


These press releases may also interest you

at 01:10
Novavax, Inc. , a late stage biotechnology company developing...

at 01:04
On August 11, 2020, the Ministry of Health of Uzbekistan released the Measures to Regulate the Circulation of Medicines, Medical Devices and Medical Facilities During the COVID-19 Pandemic, which approved those medicines in the white list to launch...

at 01:00
Ecolog performs COVID-19 tests at the Brussels Airport for travelers returning back to Belgium as well as for people departing from the airport Contract foresees the set-up of a testing facility as well as a mobile laboratory, enabling test analyses...

13 aoû 2020
Some of music's biggest names brought the fun and excitement of a music festival into viewer's homes early today for a virtual festival called Music Gives: Together #forStJude. The event was held to raise funds and awareness in support of St. Jude...

13 aoû 2020
Amgen Inc. announced today the pricing terms of its previously announced nine separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of its outstanding senior notes...

13 aoû 2020
Isagenix International, a global wellbeing company providing effective products and a supportive community, has announced four new Canada finalists in its annual total-body transformation program, the IsaBody Challenge®. The second Judging Period's...



News published on 15 july 2020 at 02:00 and distributed by: